Cutaneous adverse events to targeted therapies and immuno-therapies in children: A retrospective study of 103 patients from two tertiary haemato-oncology referral centres

Abstract

Targeted medications and immunotherapies are being developed to specifically target the pathways involv-ed in tumours. There is limited experience with these new medications and their cutaneous side-effects in the paediatric population. A retrospective study of all paediatric oncological patients treated with targeted therapies and immunotherapies between 1 January 2013 and 1 August 2020 was carried out in 2 haemato-oncological referral centres. A total of 103 children were included in the study. The median (interquartile range) age was 13 years (8.4–16.9), male:female ratio 1.5:1, median (interquartile range) follow-up was 7 months (2–18). Fifty (48%) of the children developed cutaneous adverse events. Treatment was discon-tinued in only 3 (6%) cases and was altered in only (2%) 1 case due to a cutaneous adverse event. When targeted therapies and immunotherapies for tumours in children are used, there is an increased incidence of cutaneous adverse events. Nevertheless, treatment modification or discontinuation due to cutaneous side-effects is rarely needed.